Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$83.81 - $99.0 $362,394 - $428,076
4,324 Added 175.7%
6,785 $592,000
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $187,577 - $242,433
2,461 New
2,461 $237,000
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $1.15 Million - $1.54 Million
-13,131 Reduced 84.17%
2,469 $240,000
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $337,154 - $452,552
4,166 Added 36.44%
15,600 $1.61 Million
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $384,673 - $453,873
4,682 Added 69.34%
11,434 $969,000
Q2 2022

Aug 11, 2022

BUY
$71.48 - $86.85 $482,632 - $586,411
6,752 New
6,752 $560,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cetera Advisors LLC Portfolio

Follow Cetera Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Advisors LLC with notifications on news.